insights_auto
Why is ABCL up 3.64%?
Dive Deeperchevron_right
ABCL:NASDAQ
AbCellera Biologics Inc
$12.82
arrow_upward
+3.64%(+0.45) 1D
Oct 15, 3:24:55 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$11.94
High
$12.86
Low
$11.69
Mkt. cap
4.15B
Avg. vol.
4.93M
Volume
4.68M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.41
Shares outstanding
324.05M
No. of employees
562
Open
$11.94
High
$12.86
Low
$11.69
Mkt. cap
4.15B
Avg. vol.
4.93M
Volume
4.68M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.41
Shares outstanding
324.05M
No. of employees
562
News stories
From web sources and news partners
Seeking Alpha
·
32 minutes ago
Today’s ‘stealth’ bear market is ‘one of the most significant opportunities’ – The Kobeissi Letter
Kalkine Media
·
29 minutes ago
What Puts IDT (NYSE:IDT) in Focus Across the NYSE Composite?
Barron's
·
8 minutes ago
Why This Downtrodden Paper Maker Is a Top S&P 500 Stock Today
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com